Change is hard and it can certainly be intimidating, especially in an area like drug development when there is much at stake and many complexities to manage.
Enter COVID-19.
The industry had no choice but to adapt to maintain any sort of momentum on clinical development activities. The hybrid model quickly became essential for allowing patients to continue with their trials amidst a global pandemic and the myriad health and logistical concerns that accompanied it.
The publisher surveyed 109 respondents at sponsors and CROs regarding their experiences with hybrid trials and providers of these services. Though not all reported a smooth, pain-free experience, nearly two-thirds of respondents came away with a positive overall impression of hybrid trials.
Furthermore, respondents do not seem to consider the hybrid trial model as a temporary solution to be discarded after the pandemic has subsided. 83% of respondents expect that the hybrid trial model will be used more frequently than the traditional trial model three years from now. These data are saying loud and clear that hybrid trials are here to stay.
What You Will Learn:
Pharmaceutical Organizations:
Learn from survey-takers verbatim responses on "lessons learned" from conducting hybrid trials and which aspects of hybrid trials have worked well for them
Plan ahead for managing your hybrid trials by understanding which components are considered easier to manage in a hybrid trial vs. in a traditional trial model
Make more informed provider selections by knowing how industry peers select hybrid trial providers and how providers have performed for recent users
Discover in which areas related to hybrid trials companies are investing significant resources
Service Providers:
Understand the selection drivers most important to sponsors when choosing hybrid trial providers
Learn how users of hybrid trials view your company (and your competitors) along brand metrics of leadership, familiarity with hybrid trial offerings, proposal requests, reported use, and how providers performed compared to their expectations
Discover which technologies respondents believe need the most improvement to meet hybrid trial needs and read, in respondents' own words, their unmet technology-related needs
Major Topics:
Hybrid Trial Use and Experience
Provider Selection
Provider Perceptions
Future Predictions
Study Data
Key Topics Covered:
1. Hybrid Trial Use and Experience
Primary Section Takeaways
Terminology Used
Utilization of Virtual Components
Managing Trial Components: Hybrid vs. Traditional Models
Overall Hybrid Trial Experience
Lessons Learned
Aspects That Have Gone Well
Aspects That Have Been Frustrating
Potential Benefits to Patients
Potential Benefits to Sites
Potential Benefits to Sponsors/CROs
Primary Hybrid Trial Challenge
Technologies Needing Improvement
2. Provider Selection
Primary Section Takeaways
Selection Drivers for Hybrid Trial Providers
Trust in Providers' Hybrid Trial Offerings
Sponsor Influence over Selection of Apps, Device, or Platforms when Monitoring is Outsourced
Departmental Influence over Selection of Apps, Device, or Platforms when Monitoring is In-house
3. Provider Perceptions
Primary Section Takeaways
Unaided Hybrid Trial Provider Leadership
Hybrid Trial Provider Metrics
Hybrid Trial Provider Performance
4. Future Predictions
Primary Section Takeaways
Hybrid vs. Traditional Trial Use in Three Years
Areas of Investment
Hybrid vs. Traditional Trial Costs
5. Study Data
Terminology Used
Hybrid Trial Use
Utilization of Virtual Components
Managing Trial Components: Hybrid vs. Traditional Models
The "Syndromic Multiplex Panels Markets. Strategies and Trends. Forecasts by Syndrome (Respiratory, Sepsis, GI etc.) by Place, by Product and by Country. With Market Analysis and Executive Guides. 2024 to 2028" report has been added to...
The "Immunoassay Markets. Strategies and Trends. Forecasts by Application, Technology, Product, User and by Country. With Executive Guides, Customized Forecasting and Analysis. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering....
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...